Literature DB >> 19231538

Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies.

Takaharu Oue1, Akihiro Yoneda, Shuichiro Uehara, Hiroaki Yamanaka, Masahiro Fukuzawa.   

Abstract

BACKGROUND/
PURPOSE: The overexpression of multidrug resistance (MDR)-associated genes in primary untreated tumors has been proven to be associated with worse prognosis in various pediatric malignancies. This study compared the expression of 3 MDR-associated genes, MDR1, MDR-associated protein 1 (MRP1), and lung resistance-related protein (LRP), in pediatric tumors before and after chemotherapy to elucidate the mechanism of MDR during chemotherapy.
METHODS: Surgical specimens of both primary and chemotherapy-treated tumors were obtained from 24 patients with pediatric malignancies (neuroblastoma [NB] 8; hepatoblastoma [HB] 8; Wilms tumor [WT] 4; rhabdomyosarcoma [RB] 4). The expression of MDR1, MRP1, and LRP was evaluated using the immunohistochemical staining.
RESULTS: In primary tumors, MDR1 expression was observed in 6 NBs, 8 HBs, 3 WTs, and 3 RBs. MRP1 expression was observed in 3 NBs and 1 HB. LRP expression was not detected in any of the primary tumors. After chemotherapy, MDR1 expression was observed to increase in 5 NBs, 4 HBs, 2 WTs, and 3 RBs. MRP1 expression was newly observed or increased in 7 NBs, 4 HBs, and 3 RBs. LRP expression was newly observed in 3 HBs and 2 WTs.
CONCLUSIONS: These results indicate that these 3 MDR-associated genes were upregulated after chemotherapy in various pediatric malignancies. These findings may be useful to understand the mechanism of drug resistance in pediatric malignancies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19231538     DOI: 10.1016/j.jpedsurg.2008.10.088

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  15 in total

1.  Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells.

Authors:  Xiaojuan Wu; Hui Xiao; Ruoning Wang; Lingling Liu; Chenglong Li; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

2.  Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome.

Authors:  Gisha Rose Antony; Paul Augustine; Sulfath Thottungal Parambil; Ajeesh Babu Littleflower; Jayasree Kattoor; K M Jagathnath Krishna; Lakshmi Subhadradevi
Journal:  Clin Exp Med       Date:  2022-07-09       Impact factor: 3.984

3.  Pharmacological inhibition of beta-catenin in hepatoblastoma cells.

Authors:  V Ellerkamp; J Lieber; C Nagel; J Wenz; S W Warmann; J Fuchs; S Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-12-25       Impact factor: 1.827

4.  In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma.

Authors:  Alexander Dewerth; Timo Wonner; Justus Lieber; Verena Ellerkamp; Steven W Warmann; Jörg Fuchs; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-04-18       Impact factor: 1.827

5.  Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.

Authors:  I Iacobucci; A Ferrarini; M Sazzini; E Giacomelli; A Lonetti; L Xumerle; A Ferrari; C Papayannidis; G Malerba; D Luiselli; A Boattini; P Garagnani; A Vitale; S Soverini; F Pane; M Baccarani; M Delledonne; G Martinelli
Journal:  Blood Cancer J       Date:  2012-03-09       Impact factor: 11.037

Review 6.  The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.

Authors:  Justus Lieber; Sorin Armeanu-Ebinger; Jörg Fuchs
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

Review 7.  Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma.

Authors:  Anna Alisi; William C Cho; Franco Locatelli; Doriana Fruci
Journal:  Int J Mol Sci       Date:  2013-12-18       Impact factor: 5.923

8.  The Toxic Effects of Polychemotherapy onto the Liver Are Accelerated by the Upregulated MDR of Lymphosarcoma.

Authors:  Alexandra V Sen'kova; Nadezhda L Mironova; Olga A Patutina; Tatyana A Ageeva; Marina A Zenkova
Journal:  ISRN Oncol       Date:  2012-11-29

9.  JNK1/2 Activation by an Extract from the Roots of Morus alba L. Reduces the Viability of Multidrug-Resistant MCF-7/Dox Cells by Inhibiting YB-1-Dependent MDR1 Expression.

Authors:  Youn Kyung Choi; Sung-Gook Cho; Hyeong Sim Choi; Sang-Mi Woo; Yee Jin Yun; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-24       Impact factor: 2.629

10.  3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.

Authors:  Hiroto Fukushima; Tetsuya Abe; Kazuki Sakamoto; Hiroaki Tsujimoto; Shinji Mizuarai; Shinji Oie
Journal:  BMC Cancer       Date:  2014-08-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.